Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17777671 | 0.81 | IDO1 (0.50) | MTORHDAC1HDAC3HDAC2HDAC6 | |
| Hydrochloric Acid SCHEMBL4487488 | 0.80 | IDO1 (0.51) | MTORHDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL4020664 | 0.80 | IDO1 (0.56) | MTORHDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL5347157 | 0.80 | HDAC3 (0.55) | MTORHDAC1HDAC3HDAC2HDAC6 | |
| Hydrochloric Acid SCHEMBL30996799 | 0.79 | IDO1 (0.57) | MTORHDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL11814466 | 0.77 | ALDH1A1 (0.49) | MTORHDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL18025774 | 0.77 | IDO1 (0.50) | MTORHDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL24575984 | 0.76 | MTOR (0.69) | MTORHDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL19393727 | 0.76 | IDO1 (0.41) | MTORHDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL563548 | 0.76 | LMNA (0.50) | ALDH1A1MEN1GAAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085508-B2 | Nitric oxide releasing amino acid ester compound, composition and method of use | ORAL DELIVERY TECHNOLOGY LTD. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140057873-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | FARBER MICHAEL (US) | 2014-02-27 | — | — | US | disclosed |
| US-20110195935-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | BENOIT & COTE (CA) | 2011-08-11 | — | — | US | disclosed |
| EP-2342175-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | Nitrogenix Inc. (VG) | 2011-07-13 | — | — | EP | disclosed |
| US-7838023-B2 | Furoxan compounds, compositions and methods of use | NITROMED, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090306027-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM | NITOMED, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090053328-A1 | Nitric Oxide Enhancing Glutamic Acid Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090018091-A1 | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | NICOX S.A. (FR) | 2008-12-11 | — | — | US | disclosed |
| US-20080268014-A1 | Furoxan Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7396829-B2 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20070238740-A1 | Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use | NITROMED, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070010571-A1 | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-20060189603-A1 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060009431-A1 | Nitrosated and nitrosylated compounds, compositions and methods use | NITROMED, INC. (US) | 2006-01-12 | — | — | US | disclosed |
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010571-A1 | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use | REN, ACE, AGTR1 | MTOR 2299/4885HDAC1 1868/4885HDAC3 1505/4885 |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | REN, EDNRB, ECE1 | MTOR 1590/4885HDAC1 830/4885HDAC3 718/4885 |
| US-20090053328-A1 | Nitric Oxide Enhancing Glutamic Acid Compounds, Compositions and Methods of Use | GLS, NOS1, NOS2 | MTOR 1224/4885HDAC1 2358/4885HDAC3 2215/4885 |
| US-20060009431-A1 | Nitrosated and nitrosylated compounds, compositions and methods use | TBXA2R, TXNRD3, NOS3 | MTOR 1327/4885HDAC1 3834/4885HDAC3 1657/4885 |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | REN, NOX5, NOS3 | MTOR 1573/4885HDAC1 1128/4885HDAC3 979/4885 |
| US-20110195935-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | NOS2, NOS3, NOS1 | MTOR 2672/4885HDAC1 4063/4885HDAC3 3955/4885 |
| US-20090018091-A1 | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use | NOS1, NOS3, NOS2 | MTOR 1574/4885HDAC1 4062/4885HDAC3 3797/4885 |
| US-20070238740-A1 | Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use | REN, ECE1, EDNRA | MTOR 2640/4885HDAC1 973/4885HDAC3 827/4885 |
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | REN, NOS1, NOS3 | MTOR 3065/4885HDAC1 1926/4885HDAC3 1639/4885 |
| US-20080268014-A1 | Furoxan Compounds, Compositions and Methods of Use | PTGIS, F3, PTGIR | MTOR 643/4885HDAC1 966/4885HDAC3 1380/4885 |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | AGTR2, AGTR1, REN | MTOR 880/4885HDAC1 1283/4885HDAC3 1482/4885 |
| US-20140057873-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | NOS2, NOS3, NOS1 | MTOR 2672/4885HDAC1 4063/4885HDAC3 3955/4885 |
| US-20060189603-A1 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NOS1, NOS3, REN | MTOR 1454/4885HDAC1 1338/4885HDAC3 1722/4885 |
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | GLS, NOS2, NOS1 | MTOR 1785/4885HDAC1 3197/4885HDAC3 2728/4885 |
| US-20090306027-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM | ADRB3, GNAI3, GNB1 | MTOR 3574/4885HDAC1 1558/4885HDAC3 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.